Updated
Updated · PR Newswire · Jun 26
Epigenetics Market to Reach $3.92 Billion by 2031 as Drug Discovery Drives 12% CAGR
Updated
Updated · PR Newswire · Jun 26

Epigenetics Market to Reach $3.92 Billion by 2031 as Drug Discovery Drives 12% CAGR

3 articles · Updated · PR Newswire · Jun 26

Summary

  • $3.92 billion is the projected size of the global epigenetics market in 2031, up from $2.22 billion in 2026, according to a MarketsandMarkets forecast.
  • Drug discovery, oncology research, precision medicine and biomarker development are driving adoption of epigenomic tools, with demand rising for high-throughput profiling and AI-enabled data analysis.
  • Kits and reagents held the largest product share in 2025, reflecting recurring use across methylation, chromatin and sequencing workflows; next-generation sequencing led the technology segment.
  • DNA methylation accounted for 56.2% of the market in 2025, academic and research institutes made up 45.9% of end-user demand, and North America led regions with a 41.7% share.

Insights

As the epigenetics market booms, what hurdles prevent these advanced diagnostics from reaching patients?
With AI predicting disease from our epigenome, how will we protect this deeply personal data?
Is epigenome editing truly safer than gene editing, or are we overlooking its long-term risks?